---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-164595"
form_type: "8-K/A"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:38:10.048892+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data

## Summary
- Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.
- Taletrectinib TRUST-I: 90.6% cORR in TKI-naive ROS1+ NSCLC; median PFS not reached at 23.5 mo f/u.
- Intracranial cORR 87.5% (TKI-naive) and 73.3% (TKI-pretreated) in TRUST-I; low neuro TEAEs.
- NDA accepted in China with priority review for taletrectinib; Breakthrough Therapy in US and China.
- Innovent out-license: $55M received; up to $29M regulatory + $105M commercial milestones.

## SEC filing metadata
- accession: 0001193125-24-164595
- form_type: 8-K/A
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/0001193125-24-164595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/d837366d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-164595
- JSON: https://secwatch.observer/filing/0001193125-24-164595.json
- Plain text: https://secwatch.observer/filing/0001193125-24-164595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.